Because MERTK and EGFR share PI3K/Akt and MAPK as their downstream signaling pathways, the targeting of MERTK by small molecules or monoclonal antibodies becomes a potential strategy for overcoming EGFR-TKI resistance in NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.